This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Free CME: Academic Highlights

Treatment Challenges and the Hope of Emerging Therapies in Early-Stage Alzheimer Disease

Anna D. Burke, MDa, and Liana Apostolova, MD, MScb

Published: June 15, 2021

Alzheimer disease (AD), the most common cause of dementia, is a degenerative brain disease with no cure. In the United States alone, an estimated 5.8 million people are living with AD. More than half of individuals living with AD and other dementias are not getting an accurate diagnosis and, when they do receive one, clinicians are not effectively communicating with patients and care partners regarding the illness and next steps. Additionally, prompt treatment initiation does not occur in a substantial number of newly diagnosed patients. This Academic Highlights addresses best practices for identifying patients with early-stage AD, discussing treatment goals and challenges with patients who have AD and their care partners, employing current medications approved by the U.S. Food and Drug Administration to slow symptom progression, and staying informed about emerging therapies that offer new hope for disease modification.

PDF version of article
Note: To receive credit, you must navigate through the entire online activity. Click link below.

See the entire activity

To cite: Burke AD, Apostolova L. Treatment challenges and the hope of emerging therapies in early-stage Alzheimer disease. J Clin Psychiatry. 2021;82(4):BG20044AH4C.
To share:

© Copyright 2021 Physicians Postgraduate Press, Inc.

aBarrow Neurological Institute, Phoenix, Arizona
bIndiana University School of Medicine, Indianapolis, Indiana

Volume: 82

Quick Links: Dementia , Neurologic and Neurocognitive